Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 4 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Results 1 - 20 of 50 : 1 2 3 Next »

Recs

0
Member Avatar manirg (95.25) Submitted: 8/6/2015 12:02:43 PM : Outperform Start Price: $241.16 VRX Score: +0.48

Undervalued

Recs

0
Member Avatar benyboy (< 20) Submitted: 7/14/2015 6:48:14 PM : Outperform Start Price: $237.20 VRX Score: +3.48

its good...

Recs

0
Member Avatar NechesInvst (99.67) Submitted: 6/19/2015 11:17:33 AM : Outperform Start Price: $230.93 VRX Score: +6.43

Just checking to see if Bill Ackman can pick growth companies.

Recs

0
Member Avatar stocky5 (40.42) Submitted: 6/18/2015 10:00:17 AM : Outperform Start Price: $232.34 VRX Score: +6.07

Forward PEG is 0.67 (CHEAP), with a forward growth rate of over 27%. The stock is near oversold levels, creating a good entry point. Extremely well run company with strong shareholder friendly activist oversight.

Recs

0
Member Avatar luremaster (42.85) Submitted: 5/8/2015 3:57:19 AM : Outperform Start Price: $221.42 VRX Score: +10.47

great management

Recs

0
Member Avatar AnsgarJohn (98.44) Submitted: 5/5/2015 9:00:44 AM : Underperform Start Price: $219.85 VRX Score: -10.63

http://fortune.com/2015/05/04/bill-ackman-valeant-could-be-next-berkshire-hathaway/

Recs

0
Member Avatar moneyman999 (41.23) Submitted: 2/15/2015 1:44:00 AM : Underperform Start Price: $168.17 VRX Score: -42.79

Simply overvalued,volitilty will be high but gains will be low.

Recs

0
Member Avatar freecapital (74.00) Submitted: 2/10/2015 11:37:21 PM : Outperform Start Price: $162.74 VRX Score: +46.09

Donville

Recs

0
Member Avatar 10x2 (52.68) Submitted: 1/30/2015 8:17:37 PM : Outperform Start Price: $158.00 VRX Score: +47.98

Sabrient pick.

Recs

0
Member Avatar 1russianguy (87.57) Submitted: 1/15/2015 9:17:14 AM : Outperform Start Price: $158.00 VRX Score: +47.98

Sabrient

Recs

0
Member Avatar mrudolph72 (62.19) Submitted: 1/14/2015 3:10:34 PM : Outperform Start Price: $157.00 VRX Score: +48.29

Sabrient

Recs

0
Member Avatar Defshark82 (63.23) Submitted: 12/31/2014 11:46:13 AM : Outperform Start Price: $143.88 VRX Score: +65.26

top pick JPM tracker

Recs

0
Member Avatar mlarms (20.70) Submitted: 7/31/2014 2:24:29 AM : Outperform Start Price: $118.88 VRX Score: +92.99

My big Pharma pick

Recs

0
Member Avatar chipotlepickle (98.10) Submitted: 6/15/2014 5:21:26 PM : Underperform Start Price: $118.81 VRX Score: -92.21

Running out of one time events.

Recs

0
Member Avatar ValueSwap (< 20) Submitted: 6/12/2014 3:29:27 PM : Outperform Start Price: $120.02 VRX Score: +89.98

How R&D should work and their aggressive capitalizing interest to generate a low tax rate create much fuzz about the company, which in turn give a long term holder a good entry point

Recs

0
Member Avatar IanERichards (77.13) Submitted: 6/4/2014 7:37:57 AM : Outperform Start Price: $131.15 VRX Score: +73.20

Focus on capital allocation - creative approach to making a deal

Recs

0
Member Avatar RickP (68.96) Submitted: 5/18/2014 6:17:33 PM : Outperform Start Price: $125.85 VRX Score: +77.99

Great CEO......

Fantastic future regardless of whether Allergen merger occurs or not

Recs

0
Member Avatar RLBOWERSOX (95.67) Submitted: 3/31/2014 4:40:45 PM : Outperform Start Price: $132.07 VRX Score: +69.32

One of the final four

Recs

0
Member Avatar mrwrong (< 20) Submitted: 3/29/2014 2:06:48 PM : Underperform Start Price: $129.27 VRX Score: -72.55

growth will stall as company comes a cropper, with a bridge too far. most all- do, but i like it now.

Recs

0
Member Avatar motto1628 (52.93) Submitted: 3/25/2014 4:05:57 PM : Outperform Start Price: $132.26 VRX Score: +68.73

- genius CEO in acquisition
- diversified pharmaceutical products
- stock advisor pick

Results 1 - 20 of 50 : 1 2 3 Next »

Featured Broker Partners


Advertisement